German study rejects neuroblastoma screening
This article was originally published in Clinica
A mass early-detection programme for neuroblastoma, a form of cancer, in children aged 10-12 months serves no purpose, claims a recent German report published earlier this month in the New England Journal of Medicine. Speaking at a conference in Bonn last week, Dr Freimut Schilling from the Olga Hospital in Stuttgart, secretary of the German model project for neuroblastoma early-detection, said that such screening was pointless as it neither reduced the number of deaths, nor the number of children reaching the advanced stage of the illness.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.